A post-marketing survey evaluating the safety and efficacy of a fixed-dose single-pill combination of cilnidipine and valsartan in patients with hypertension: Real-world JSH 2014 and 2019 implementations

References

• Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, et al. The Japanese Society of hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37:253–390.
   PubMed Web of Science ®Google Scholar
• Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshide S, Ikeda S, Ishimitsu T, et al. The Japanese Society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235–481.
   PubMed Web of Science ®Google Scholar
• Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96:e5641. DOI:10.1097/MD.0000000000005641.
   PubMed Web of Science ®Google Scholar
• Nguyen TP, Schuiling-Veninga CC, Nguyen TB, Vu TH, Wright EP, Postma MJ. Adherence to hypertension medication: quantitative and qualitative investigations in a rural Northern Vietnamese community. PLoS One. 2017;12:e0171203. DOI:10.1371/journal.pone.0171203.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399–407. DOI:10.1161/HYPERTENSIONAHA.109.139816.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, et al. ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, et al. ESC/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953–2041.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2018;71:1269–324.
   PubMed Web of Science ®Google Scholar
• Chiang CE, Wang TD, Ueng KC, Lin TH, Yeh HI, Chen CY, Wu YJ, Tsai WC, Chao TH, Chen CH, et al. guidelines of the Taiwan Society of cardiology and the Taiwan Hypertension society for the management of hypertension. J Chin Med Assoc. 2015;78:1–47.
   PubMed Web of Science ®Google Scholar
• Takahara A. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther. 2009;27:124–39. DOI:10.1111/j.1755-5922.2009.00079.x.
   PubMed Web of Science ®Google Scholar
• Uneyama H, Takahara A, Dohmoto H, Yoshimoto R, Inoue K, Akaike N. Blockade of N-type Ca2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones. Br J Pharmacol. 1997;122:37–42. DOI:10.1038/sj.bjp.0701342.
   PubMed Web of Science ®Google Scholar
• Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs. Arch Intern Med. 1995;155:1361–68. DOI:10.1001/archinte.1995.00430130027004.
   PubMed Web of Science ®Google Scholar
• Imai Y, Kario K, Shimada K, Kawano Y, Hasebe N, Matsuura H, Tsuchihashi T, Ohkubo T, Kuwajima I, Miyakawa M. The Japanese Society of hypertension guidelines for self-monitoring of blood pressure at home (Second Edition). Hypertens Res. 2012;35:777–95. DOI:10.1038/hr.2012.56.
   PubMed Web of Science ®Google Scholar
• Kario K, Matsuda S, Nagahama S, Kurose Y, Sugii H, Teshima T, Suzuki N. Single-pill combination of cilnidipine, an L-/N-type calcium channel blocker, and valsartan effectively reduces home pulse pressure in patients with uncontrolled hypertension and sympathetic hyperactivity: the HOPE-Combi survey. J Clin Hypertens. in press.
   Web of Science ®Google Scholar
• Nagahama S, Norimatsu T, Maki T, Yasuda M, Tanaka S. The effect of combination therapy with an L/N-Type Ca(2+) channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients: an observational study conducted in Japan. Hypertens Res. 2007;30:815–22. DOI:10.1291/hypres.30.815.
   PubMed Web of Science ®Google Scholar
• Gillman MW, Kannel WB, Belanger A, D’Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham study. Am Heart J. 1993;125:1148–54. DOI:10.1016/0002-8703(93)90128-V.
   PubMed Web of Science ®Google Scholar
• Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005;352:1951–58. DOI:10.1056/NEJMoa043012.
   PubMed Web of Science ®Google Scholar
• Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. Am Heart J. 1991;121:172–77. DOI:10.1016/0002-8703(91)90970-S.
   PubMed Web of Science ®Google Scholar
• Kario K, Ando S, Kido H, Nariyama J, Takiuchi S, Yagi T, Shimizu T, Eguchi K, Ohno M, Kinoshita O, et al. The effects of the L/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE. J Clin Hypertens (Greenwich). 2013;15:133–42.
   PubMed Web of Science ®Google Scholar
• Aoki S, Hosomi N, Nezu T, Teshima T, Sugii H, Nagahama S, Kurose Y, Maruyama H, Matsumoto M. Blood pressure control with cilnidipine treatment in Japanese post-stroke hypertensive patients: the CA-ATTEND study. Clin Exp Hypertens. 2017;39:225–34. DOI:10.1080/10641963.2016.1235183.
   PubMed Web of Science ®Google Scholar
• Nagahama S, Iwayama S. The safety and efficacy of administration with combination 10 mg cilnidipine and 80 mg valsartan in hypertensive patients. J New Rem Clin. 2016;65:792–802.
   Google Scholar
• Hozawa A, Ohkubo T, Kikuya M, Ugajin T, Yamaguchi J, Asayama K, Metoki H, Ohmori K, Hoshi H, Hashimoto J, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens. 2004;17:1005–10.
   PubMed Web of Science ®Google Scholar
• Nauman J, Janszky I, Vatten LJ, Wisloff U. Temporal changes in resting heart rate and deaths from ischemic heart disease. JAMA. 2011;306:2579–87. DOI:10.1001/jama.2011.1826.
   PubMed Web of Science ®Google Scholar
• Hoshide S, Kario K, Ishikawa J, Eguchi K, Shimada K. Comparison of the effects of cilnidipine and amlodipine on ambulatory blood pressure. Hypertens Res. 2005;28:1003–08. DOI:10.1291/hypres.28.1003.
   PubMed Web of Science ®Google Scholar
• Sakata K, Shirotani M, Yoshida H, Nawada R, Obayashi K, Togi K, Miho N. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension. 1999;33:1447–52. DOI:10.1161/01.HYP.33.6.1447.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim SH, Kang SH, Cho JH, Cho Y, Oh IY, Yoon CH, Lee HY, Youn TJ, Chae IH, et al. Blood pressure control and cardiovascular outcomes: real-world implications of the 2017 ACC/AHA hypertension guideline. Sci Rep. 2018;8:13155.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Jia L, Lu B, Gu G, Hu H, Zhang Z, Bai L, Cui W. Updated hypertension prevalence, awareness, and control rates based on the 2017ACC/AHA high blood pressure guideline. J Clin Hypertens (Greenwich). 2019;21:758–65. DOI:10.1111/jch.13564.
   PubMed Web of Science ®Google Scholar